ARTICLE | Clinical News

Viekirax paritaprevir regulatory update

November 24, 2014 8:00 AM UTC

EMA’s CHMP recommended approval for an all-oral, interferon-free treatment of Exviera dasabuvir and Viekirax ombitasvir/paritaprevir/ritonavir with or without ribavirin to treat chronic HCV genotypes 1 and 4 infection. AbbVie expects a final decision by 1Q15 for both MAAs. The combination is under Priority Review by FDA to treat HCV genotype 1 infection, with a decision expected by year end. ...